Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johannes Vermehren

Showing results (1-10 of 88) with videos related to

Pageof 9
Sort By:
Journal of Hepatology|September 20, 2016
Diagnostics in hepatitis C: The end of response-guided therapy?Benjamin Maasoumy, Johannes Vermehren
European Journal of Medical Research|August 5, 2011
New hepatitis C therapies in clinical developmentJohannes Vermehren, Christoph Sarrazin
Best Practice & Research. Clinical Gastroenterology|December 4, 2012
The role of resistance in HCV treatmentJohannes Vermehren, Christoph Sarrazin
Transplantation|January 28, 2016
New HCV Therapies and Liver TransplantationJens M Werner, Johannes Vermehren
Journal of Hepatology|August 22, 2008
Treatment predictors of a sustained virologic response in hepatitis B and CAnnika Kau, Johannes Vermehren, Christoph Sarrazin
MMW Fortschritte Der Medizin|August 25, 2012
[Chronic hepatitis C: improved cure rates with new approved medications]Georgios Grammatikos, Johannes Vermehren, Stefan Zeuzem
World Journal of Gastroenterology|December 4, 2014
Colon capsule endoscopy: current status and future directionsAndrea O Tal, Johannes Vermehren, Jörg G Albert
Journal of Hepatology|July 28, 2016
Reply to: "HCV RNA kinetics on-treatment do not predict sustained virologic response in HCV genotype 3 patients receiving sofosbuvir and ribavirin"Benjamin Maasoumy, Johannes Vermehren, Heiner Wedemeyer, et al.
Journal of Hepatology|July 15, 2018
Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infectionJohannes Vermehren, James S Park, Ira M Jacobson, et al.
Zeitschrift Fur Gastroenterologie|November 3, 2016
To treat or not to treat - Successful hepatitis C virus eradication in a patient with advanced hepatocellular carcinoma and complete response to sorafenibOliver Waidmann, Jan Peveling-Oberhag, Katrin Eichler, et al.
Pageof 9

Showing results (1-10 of 88) with videos related to

Sort By:
Pageof 9
Journal of Hepatology|September 20, 2016
Diagnostics in hepatitis C: The end of response-guided therapy?Benjamin Maasoumy, Johannes Vermehren
European Journal of Medical Research|August 5, 2011
New hepatitis C therapies in clinical developmentJohannes Vermehren, Christoph Sarrazin
Best Practice & Research. Clinical Gastroenterology|December 4, 2012
The role of resistance in HCV treatmentJohannes Vermehren, Christoph Sarrazin
Transplantation|January 28, 2016
New HCV Therapies and Liver TransplantationJens M Werner, Johannes Vermehren
Journal of Hepatology|August 22, 2008
Treatment predictors of a sustained virologic response in hepatitis B and CAnnika Kau, Johannes Vermehren, Christoph Sarrazin
MMW Fortschritte Der Medizin|August 25, 2012
[Chronic hepatitis C: improved cure rates with new approved medications]Georgios Grammatikos, Johannes Vermehren, Stefan Zeuzem
World Journal of Gastroenterology|December 4, 2014
Colon capsule endoscopy: current status and future directionsAndrea O Tal, Johannes Vermehren, Jörg G Albert
Journal of Hepatology|July 28, 2016
Reply to: "HCV RNA kinetics on-treatment do not predict sustained virologic response in HCV genotype 3 patients receiving sofosbuvir and ribavirin"Benjamin Maasoumy, Johannes Vermehren, Heiner Wedemeyer, et al.
Journal of Hepatology|July 15, 2018
Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infectionJohannes Vermehren, James S Park, Ira M Jacobson, et al.
Zeitschrift Fur Gastroenterologie|November 3, 2016
To treat or not to treat - Successful hepatitis C virus eradication in a patient with advanced hepatocellular carcinoma and complete response to sorafenibOliver Waidmann, Jan Peveling-Oberhag, Katrin Eichler, et al.
Pageof 9